Lion Corporation4912.T

Lion is not a growth story and never was. Revenue grew 11% across the last decade and the share count fell ; the entire move in earnings — diluted EPS up 154%, ¥39 to ¥100 — came from a margin that swung from 4.3% to a 12.4% COVID peak to a 5.1% trough and back to 8.6%. The company is a domestic margin recoverer with a fortress balance sheet, and the question the dossier turns on is whether the recovery from the 2023 trough is the start of a structurally higher margin or simply a cyclical rebound the share price has already paid for.

The cellular segment data sharpens that question, because the recovery is domestic and specific rather than broad. The Consumer Products core operating margin moved from 6.5% to 8.5% in a single year, and management attributes the gain to profit-structure-reform measures — an internal lever, not the oleochemical reversal alone. Underneath it, oral care grew +4.6% on accepted premiumisation while fabric care fell −2.2% and pharmaceutical −7.9%. So the domestic engine is one franchise pricing value and several categories doing nothing, and the margin step-up rests on whether the oral-care mix shift is durable or whether the input-cost tailwind that flattered FY2025 is simply fading.

There is a second point that reframes the case. The dossier was inherited as a patrimonial value story : a defensive franchise sitting on ¥85bn of net cash that the market was treating as a neutral cushion and that TSE pressure would force into the open. Read against the certified balance sheet, that premise has weakened. By March 2026 the net cash was down to ¥42.9bn — the Vietnamese acquisition of Merap consumed roughly half of it — leaving the dormant capital at about 10% of the market cap rather than the ~19% the inherited reading leaned on. Valued part by part on normalised core operating profit, the sum of the parts lands on the market capitalisation. The patrimonial discount everyone was waiting to harvest is mostly not there.

What that leaves is a recovery that is real, domestically driven, and largely in the price. At 17.3x forward earnings on a consensus EPS already marked down 7% for the 2025 one-offs, the multiple is full for a defensive with no organic growth. The remaining upside is in two things the price does not yet hold. One is whether the domestic margin proves structural — a Consumer Products core moving durably through 9% rather than settling back toward 8%. The other is whether the capital that is left gets mobilised toward shareholders faster than the ~30% payout and episodic buybacks the market assumes, rather than into more Asian M&A at a 4.3% margin.

The position framing is patient observation. There is no margin of safety in the price and the weighted asymmetry is slightly negative ; the bias is long but conditional on catalysts that are not signalled today. Conviction is moderate. The things worth watching are the Consumer Products margin print and the first read on how the Vietnamese capital is spent ; both are observable on the published calendar.

The cleanest way to read the last decade is as a single margin cycle laid over a flat top line. Revenue grew 11% across ten years, from ¥378.7bn to ¥422.1bn, and even that number is partly an artefact : a revenue-recognition reset between FY2017 and FY2018 cut reported sales from ¥410.5bn to ¥349.4bn, so any trend drawn through the middle is unreliable. The thing that actually moved was the margin. EBIT margin ran 4.3% in 2015, reached a 12.4% COVID-hygiene peak in 2020, collapsed to 5.1% in 2023 as the oleochemical spread closed, and has recovered to 8.6%. Return on capital traced the same arc — 7.7%, a 14.9% peak in 2018, a 5.6% trough, and back to 8.8%. Every yen of value creation came from that margin and none from volume, which makes a ten-year-average multiple useless : the average is dragged down by the trough years.

Three management decisions explain the shape. The capital expenditure peak of ¥37.3bn in FY2021 — against ¥9–15bn in a normal year — was committed at the top of COVID hygiene demand, drove free cash flow to −¥18.0bn, and lifted property, plant and equipment to a ¥172.0bn peak just before demand normalised and the oleochemical scissor closed : an expensive timing error in industrial allocation, though not a fatal one. The net cash was left chronically under-mobilised — payout stuck near 30%, roughly ¥20bn returned over ten years against a position structurally above ¥80bn, compressing return on equity to ~9%. And twenty years of Asian expansion never reached accretive scale, leaving Northeast Asia a value sink. The discipline since — two ¥10bn buybacks in FY2022 and FY2024, a DPS raised 11% to ¥30, ~4.65m treasury shares cancelled — is corrective and real. But the same dormant cash that funds buybacks just funded the Vietnamese acquisition, and which of those two uses defines the next decade is the open question.

The engine only resolves once the consolidated line is broken into segments, because they are economically different businesses. The certified 9M FY2025 maille shows the spread plainly. Consumer Products, the domestic core, earns an 8.5% core operating margin. Industrial earns 5.3%. Overseas earns 4.3% — half the domestic level. And Overseas itself is two opposed units : Southeast and South Asia (Thailand, Malaysia) at 6.0% and growing core profit +34.9%, against Northeast Asia (China, Korea) at 1.5% and shrinking core profit −39.6%. A single consolidated 7.3% margin is the weighted average of a domestic franchise being repaired and an Asian periphery pulling in two directions.

Where the pricing power actually lives matters here, because consolidated growth flatters it. Oral care grew +4.6% on premiumisation the consumer accepted — SYSTEMA, CLINICA PRO, Dent Health DX Premium — and that is real pricing power, the ability to move the mix up without losing the customer. The rest of the domestic book does not have it : fabric care fell −2.2% and pharmaceutical −7.9%, both subject to Kao and P&G and to a partial, lagged pass-through of input costs that produced the 2023 trough in the first place. So the +1.6% in Consumer Products sales is one franchise pricing value and the others holding ground, and the quality of the line is concentrated in oral care.

The cost that explains most of the margin volatility is the oleochemical spread — fats, surfactants and palm derivatives — which moves on a 12–24 month lag, so the input shock lands before the price response catches up. Its reversal drove the FY2024–2025 recovery as surely as its tightening drove the FY2023 trough. Lion manages it differently from a premium peer such as Rohto, which prices through : Lion absorbs more, and offsets it with internal cost-structure reform — the lever that added ~200 basis points to the Consumer Products margin in a year — rather than with price. The new cost in formation is the Asian build-out : a plant under construction in Bangladesh and the integration of the Vietnamese acquisition, both of which weigh on the overseas margin before any scale benefit arrives.

Cash conversion is sound in absolute terms and weak in efficiency. Free cash flow ran ¥22.6bn in FY2025, about 62% of EBIT, on a 5.3% FCF margin — the weakest conversion of the four 03b platforms. The structural drag is working capital : the cash conversion cycle has lengthened from 23 days in FY2020 to 66 now, with days payable falling from 132 to 87, as the heavy-working-capital household book consumes the cash the oral-care core generates. Against that sits a balance sheet doing little : ¥42.9bn of net cash at the spot, an overfunded pension, an equity ratio of 63.7%. That dormant capital is the real option in the name, and the Vietnamese acquisition is the first evidence of how management intends to spend it.